Commercial Capsules: Autoimmune Positioning; Sanofi In China; Migraine Race; BMS Deal; Clinical Advances
AbbVie outlines how it will stay top dog in autoimmune therapy; Dermira licenses lebrikizumab, threatening pressure on Sanofi/Regeneron's Dupixent; Sanofi has driven up vaccine sales in China after responding to new government distribution rules; Lilly plans a migraine filing; FibroGen, Myokardia and Hansa Medical advance in the clinic and Bristol-Myers shells out up to $2.3bn to turn cold tumors hot. Commercial Capsules rounds up key commercial news reported recently by sister publication Scrip.
You may also be interested in...
Just months ago, China's category two vaccines sector barely showed signs of life after being hit hard by a quality scandal. It now helps Sanofi deliver double-digit growth, showing what difference adapting to regulatory change can make in China.
Phase II data for FibroGen's first-in-class therapy for idiopathic pulmonary fibrosis panrevlumab has sent its shares soaring and could have potential partners scrambling.
Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet medical need.